Interestingly, PGZ is more effective in treating fatty liver disease than RGZ, the more potent PPARγ agonist (Promrat et al., 2004; Ratziu et al., 2008; Ratziu et al., 2010), suggesting that moderate binding is more effective. Here, PPARG is linked to fatty liver disease.